Limits...
Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression.

Patel M, Carritt K, Lane J, Jayappa H, Stahl M, Bourgeois M - Clin. Vaccine Immunol. (2015)

Bottom Line: Group A was significantly protected compared to those in groups B (P < 0.013) and C (P < 0.0001).No difference was found between groups B and C (P > 0.063).The viral RNA loads were significantly lower in group A than in group B at weeks 7 to 9 (P < 0.01).

View Article: PubMed Central - PubMed

Affiliation: Merck Animal Health, Elkhorn, Nebraska, USA.

No MeSH data available.


Related in: MedlinePlus

Serum IgG antibodies to FeLV vaccination phase. All cats were negative for FeLV antibody prior to vaccination on study day 0. Ten of 11 cats in the Nobivac feline 2-FeLV group were positive for FeLV antibody on study days 20 (average S/P ratio, 3.0544 ± 1.007) and 111 (average S/P ratio, 1.002 ± 0.48). The PureVax recombinant FeLV-vaccinated cats and control-group cats remained antibody negative during the vaccination phase of the study. Statistically significant (P = 0.00) differences were seen between the Nobivac feline 2-FeLV group and the Purevax recombinant FeLV group (*) and the control group (**).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4478526&req=5

Figure 1: Serum IgG antibodies to FeLV vaccination phase. All cats were negative for FeLV antibody prior to vaccination on study day 0. Ten of 11 cats in the Nobivac feline 2-FeLV group were positive for FeLV antibody on study days 20 (average S/P ratio, 3.0544 ± 1.007) and 111 (average S/P ratio, 1.002 ± 0.48). The PureVax recombinant FeLV-vaccinated cats and control-group cats remained antibody negative during the vaccination phase of the study. Statistically significant (P = 0.00) differences were seen between the Nobivac feline 2-FeLV group and the Purevax recombinant FeLV group (*) and the control group (**).

Mentions: Antibodies (IgG) to FeLV were detected using indirect ELISA. All cats were negative for the FeLV antibody on study day 0, prior to vaccination. Ten of 11 cats in the Nobivac feline 2-FeLV group were positive for the FeLV antibody on study days 20 (S/P ratio, 3.0544 ± 1.007) and 111 (S/P ratio, 1.002 ± 0.48). One cat was not tested on study day 20 due to a low serum sample volume. All cats in the PureVax recombinant FeLV group as well as the control group remained negative for the FeLV antibody through the entire vaccination phase. Levels of the IgG antibody in cats that received Nobivac feline 2-FeLV were significantly higher at days 20 and 111 than in those that received Purevax recombinant FeLV (P = 0.00) and in controls (P = 0.00) (Fig. 1).


Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression.

Patel M, Carritt K, Lane J, Jayappa H, Stahl M, Bourgeois M - Clin. Vaccine Immunol. (2015)

Serum IgG antibodies to FeLV vaccination phase. All cats were negative for FeLV antibody prior to vaccination on study day 0. Ten of 11 cats in the Nobivac feline 2-FeLV group were positive for FeLV antibody on study days 20 (average S/P ratio, 3.0544 ± 1.007) and 111 (average S/P ratio, 1.002 ± 0.48). The PureVax recombinant FeLV-vaccinated cats and control-group cats remained antibody negative during the vaccination phase of the study. Statistically significant (P = 0.00) differences were seen between the Nobivac feline 2-FeLV group and the Purevax recombinant FeLV group (*) and the control group (**).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4478526&req=5

Figure 1: Serum IgG antibodies to FeLV vaccination phase. All cats were negative for FeLV antibody prior to vaccination on study day 0. Ten of 11 cats in the Nobivac feline 2-FeLV group were positive for FeLV antibody on study days 20 (average S/P ratio, 3.0544 ± 1.007) and 111 (average S/P ratio, 1.002 ± 0.48). The PureVax recombinant FeLV-vaccinated cats and control-group cats remained antibody negative during the vaccination phase of the study. Statistically significant (P = 0.00) differences were seen between the Nobivac feline 2-FeLV group and the Purevax recombinant FeLV group (*) and the control group (**).
Mentions: Antibodies (IgG) to FeLV were detected using indirect ELISA. All cats were negative for the FeLV antibody on study day 0, prior to vaccination. Ten of 11 cats in the Nobivac feline 2-FeLV group were positive for the FeLV antibody on study days 20 (S/P ratio, 3.0544 ± 1.007) and 111 (S/P ratio, 1.002 ± 0.48). One cat was not tested on study day 20 due to a low serum sample volume. All cats in the PureVax recombinant FeLV group as well as the control group remained negative for the FeLV antibody through the entire vaccination phase. Levels of the IgG antibody in cats that received Nobivac feline 2-FeLV were significantly higher at days 20 and 111 than in those that received Purevax recombinant FeLV (P = 0.00) and in controls (P = 0.00) (Fig. 1).

Bottom Line: Group A was significantly protected compared to those in groups B (P < 0.013) and C (P < 0.0001).No difference was found between groups B and C (P > 0.063).The viral RNA loads were significantly lower in group A than in group B at weeks 7 to 9 (P < 0.01).

View Article: PubMed Central - PubMed

Affiliation: Merck Animal Health, Elkhorn, Nebraska, USA.

No MeSH data available.


Related in: MedlinePlus